Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SHE:300255)
China · Delayed Price · Currency is CNY 22.50
-0.32 (-1.40%)
Sep 11, 2026, 3:04 PM CST
SHE:300255 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 20,679 | 57,074 | 18,372 | 11,957 | 5,036 | 7,472 | |
Market Cap Growth | -52.35% | 210.66% | 53.65% | 137.41% | -32.59% | 31.26% |
Enterprise Value | 23,258 | 59,375 | 20,352 | 14,091 | 6,817 | 8,617 |
Last Close Price | 22.50 | 62.10 | 19.99 | 13.01 | 5.47 | 8.09 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | - | - | 287.58 | 31.99 |
Forward PE | - | 12.44 | 12.44 | 12.44 | 12.44 | 12.44 |
PS Ratio | 24.06 | 65.22 | 17.82 | 8.48 | 2.16 | 2.52 |
PB Ratio | 18.04 | 48.86 | 11.96 | 6.64 | 1.65 | 2.43 |
P/TBV Ratio | 23.78 | 64.09 | 14.65 | 8.02 | 1.80 | 2.68 |
P/OCF Ratio | - | 1024.98 | 326.80 | 354.53 | 1611.41 | 2602.11 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 27.06 | 67.85 | 19.74 | 9.99 | 2.92 | 2.90 |
EV/EBITDA Ratio | - | - | - | - | 41.33 | 22.68 |
EV/EBIT Ratio | - | - | - | - | 63.13 | 26.59 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 2.44 | 2.20 | 1.66 | 1.32 | 0.82 | 0.57 |
Debt / EBITDA Ratio | - | - | - | - | 15.10 | 4.58 |
Net Debt / Equity Ratio | 2.29 | 2.09 | 1.50 | 1.19 | 0.55 | 0.39 |
Net Debt / EBITDA Ratio | -17.32 | -14.44 | -21.66 | -1.99 | 10.26 | 3.15 |
Net Debt / FCF Ratio | -10.91 | -36.01 | -12.57 | -10.39 | -3.95 | -3.92 |
Asset Turnover | 0.19 | 0.20 | 0.23 | 0.27 | 0.42 | 0.61 |
Inventory Turnover | 0.68 | 0.65 | 0.62 | 0.85 | 0.56 | 0.60 |
Quick Ratio | 0.25 | 0.18 | 0.25 | 0.29 | 0.72 | 0.52 |
Current Ratio | 0.75 | 0.69 | 0.91 | 1.19 | 2.18 | 1.97 |
Return on Equity (ROE) | -26.68% | -27.18% | -15.83% | -51.43% | 0.33% | 7.81% |
Return on Assets (ROA) | -3.02% | -3.33% | -2.45% | -13.46% | 1.20% | 4.15% |
Return on Invested Capital (ROIC) | -5.86% | -6.34% | -4.60% | -26.38% | 1.34% | 7.22% |
Return on Capital Employed (ROCE) | -10.70% | -12.60% | -7.70% | -42.80% | 2.50% | 9.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | -1.67% | -0.63% | -1.36% | -10.37% | 0.35% | 3.13% |
FCF Yield | -1.16% | -0.12% | -1.00% | -1.72% | -8.50% | -4.08% |
Dividend Yield | - | - | - | - | 0.09% | 0.32% |
Payout Ratio | - | - | - | - | 708.02% | 26.50% |
Buyback Yield / Dilution | 9.35% | 0.68% | -0.58% | -4.91% | 6.27% | 0.23% |
Total Shareholder Return | 9.35% | 0.68% | -0.58% | -4.91% | 6.37% | 0.55% |